Abstract Objective To investigate the efficacy of Zibitai combined with Atorvastatin Calcium in elderly patients with hyperlipidemia. Methods From January 2019 to January 2021, 120 elderly patients with hyperlipidemia in Guangxi International Zhuang Medical Hospital were divided into control group (60 cases, Atorvastatin Calcium 20 mg, once a day) and study group (60 cases, 240 mg, twice a day+Atorvastatin Calcium 10 mg, once a day) by random number table method, all treated for 12 weeks. The changes in blood lipid, liver and kidney function, creatine kinase (CK) and fasting plasma glucose (FPG) were deterimined, and adverse events were recorded in both groups. Results After treatment, there was no statistically significant difference in high density lipoprotein-cholesterol (HDL-C) of the two groups compared with before treatment (P ＞ 0.05), while the levels of total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C) and triglyceride (TG) were lower than those before treatment, the differences were statistically significant (P ＜ 0.05). There were no significant differences in TC, LDL-C, HDL-C, and TG between the two groups after treatment (P ＞ 0.05). There were no significant differences in the levels of FPG, creatinine, CK, and ALT between the two groups after treatment compared with those before treatment and between the groups (P ＞ 0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion The efficacy and safety of Zibitai combined with low-dose Atorvastatin Calcium in the treatment of elderly patients with hyperlipidemia are good.
LI Jian ZHOU Xinling▲ WANG Zhixiao WANG Yi. Clinical effect of Zibitai combined with low-dose Atorvastatin Calcium in the treatment of elderly patients with hyperlipidemia#br#[J]. 中国医药导报, 2022, 19(13): 161-164.
[1] He N，Ye H. Exercise and Hyperlipidemia [J]. Adv Exp Med Biol，2020，1228：79-90.
[2] Karr S. Epidemiology and management of hyperlipidemia [J].Am J Manag Care，2017，23（9 Suppl）：S139-S148.
[3] Flora GD，Nayak MK. A Brief Review of Cardiovascular Diseases，Associated Risk Factors and Current Treatment Regimes [J]. Curr Pharm Des，2019，25（38）：4063-4084.
[4] Miao J，Zang X，Cui X，et al. Autophagy，Hyperlipidemia，and Atherosclerosis [J]. Adv Exp Med Biol，2020，1207：237-264.
[5] 康晨瑜，王以新，刘俊梅，等.不同他汀类药物对围绝经期血脂异常患者血脂水平的影响[J].中国医药，2020，15（3）：386-389.
[6] Nikolic D，Banach M，Chianetta R，et al. An overview of statin-induced myopathy and perspectives for the future [J]. Expert Opin Drug Saf，2020，19（5）：601-615.
[7] Reston JT，Buelt A，Donahue MP，et al. Interventions to Improve Statin Tolerance and Adherence in Patients at Risk for Cardiovascular Disease：A Systematic Review for the 2020 U.S. Department of Veterans Affairs and U.S. Department of Defense Guidelines for Management of Dyslipidemia [J]. Ann Intern Med，2020，173（10）：806-812.
[8] Cote DJ，Rosner BA，Smith-Warner SA，et al. Statin use，hyperlipidemia，and risk of glioma [J]. Eur J Epidemiol，2019，34（11）：997-1011.
[9] HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant：trial design，pre-specified muscle and liver outcomes，and reasons for stopping study treatment [J]. Eur Heart J，2013，34（17）：1279-1291.
[10] Xu D，Hu J，Wu Q，et al. Efficacy and safety of Zhibitai in combination with atorvastatin for lipid lowering in patients with coronary heart disease [J]. Oncotarget，2017，9（10）：9489-9497.
[11] 熊敏.脂必泰胶囊对高脂血症患者血脂指标及炎症反应的影响[J].中国处方药，2019，17（12）：108-109.
[12] 杨海燕，韩景辉.脂必泰胶囊治疗颈动脉粥样硬化的疗效观察[J].中西医结合心脑血管病杂志，2018，16（18）：2696-2697.
[13] 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南（2016年修订版）[J].中国循环杂志，2017，31（10）：937-950.
[14] Mach F，Baigent C，Catapano AL，et al. 2019 ESC/EAS guide-lines for the management of dyslipidaemias：lipid modification to reduce cardiovascular risk [J]. Eur Heart J，2020，41（1）：111-188.
[15] 李勇，赵水平，叶平，等.中国血脂异常门诊患者调脂治疗一级和二级预防达标现状：DYSIS-China亚组分析[J].中华心血管病杂志，2016，44（8）：665-670.
[16] Liu MW，Liu R，Wu HY，et al. Atorvastatin has a protective effect in a mouse model of bronchial asthma through regulating tissue transglutaminase and triggering receptor expressed on myeloid cells-1 expression [J]. Exp Ther Med，2017，14（2）：917-930.
[17] Angelidi AM，Stambolliu E，Adamopoulou KI，et al. Is Atorvastatin Associated with New Onset Diabetes or Deterioration of Glycemic Control? Systematic Review Using Data from 1.9 Million Patients [J]. Int J Endocrinol，2018， 2018：8380192.
[18] Liu X，Zhang W，Zhao M，et al. Effect of atorvastatin treatment on circulating adiponectin： a meta-analysis of randomized controlled trials [J]. Lipids Health Dis，2019，18（1）：228.
[19] Cicero AFG，Fogacci F，Banach M. Red Yeast Rice for Hypercholesterolemia [J]. Methodist Debakey Cardiovasc J，2019，15（3）：192-199.
[20] Wang TJ，Lien AS，Chen JL，et al. A Randomized Clinical Efficacy Trial of Red Yeast Rice （Monascus pilosus） Against Hyperlipidemia [J]. Am J Chin Med，2019，47（2）：323-335.
[21] 楼陆军，罗洁霞，高云.山楂的化学成分和药理作用研究概述[J].中国药业，2014，23（3）：92-94.
[22] 徐硕，夏路风，金鹏飞，等.泽泻的化学成分及生物活性研究进展[J].中国医药导报，2015，12（27）：47-51.
[23] 田景平，温泽淮，郭新峰，等.脂必泰与阿托伐他汀比较治疗高脂血症疗效及安全性的系统评价[J].中国循证医学杂志，2013，13（9）：1116-1122.
[24] 谭斌，吴一君，余波.瑞舒伐他汀钙片联合脂必泰治疗高脂血症的临床效果[J].中国当代医药，2021，28（13）：64-66.
[25] 花继平.脂必泰胶囊治疗高脂血症的疗效观察[J].中西医结合心血管病电子杂志，2020，8（10）：67-68.
[26] Chen M，Li Y，Men L，et al. Efficacy and safety of Zhibitai in treating coronary heart disease patients with hyperlipemia：A protocol for systematic review and meta-analysis [J]. Medicine （Baltimore），2020，99（36）：e21991.
[27] Zhao Y，Peng R，Zhao W，et al. Zhibitai and low-dose atorvastatin reduce blood lipids and inflammation in patients with coronary artery disease [J]. Medicine（Baltimore），2017，96（7）：e6104.
[28] 潘敏.瑞舒伐他汀联合脂必泰治疗高脂血症的疗效及对血液流变学的影响[J].中国处方药，2021，19（2）：81-82.
